L. Esserman
- Statistics and Probability top 2%
- Cancer Research top 10%
- Breast Cancer Treatment Studies 11
- Cancer Genomics and Diagnostics 6
-
- Cancer Treatment and Pharmacology 3
- Economics and Econometrics top 10%
- Health Systems, Economic Evaluations, Quality of Life 3
-
- BRCA gene mutations in cancer 3
-
- Breast Implant and Reconstruction 3
-
- Advanced Breast Cancer Therapies 3
-
- MRI in cancer diagnosis 2
L. Esserman
35 papers receiving 674 citations
Peers
Comparison fields: 5 of 85
- Statistics and Probability 207
- Cancer Research 261
- Oncology 168
- Economics and Econometrics 106
- Management Science and Operations Research 46
Countries citing papers authored by L. Esserman
This map shows the geographic impact of L. Esserman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Esserman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Esserman more than expected).
Fields of papers citing papers by L. Esserman
This network shows the impact of papers produced by L. Esserman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Esserman. The network helps show where L. Esserman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside L. Esserman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 0 | |
| 5 | 2023 | 2 | |
| 6 | 2023 | 0 | |
| 7 | 2018 | 6 | |
| 8 | 2016 | 27 | |
| 9 | 2016 | 0 | |
| 10 | 2013 | 4 | |
| 11 | 2011 | 1 | |
| 12 | 2011 | 1 | |
| 13 | 2009 | 496 | |
| 14 | 2009 | 1 | |
| 15 | 2009 | 1 | |
| 16 | 2009 | 2 | |
| 17 | 2004 | 10 | |
| 18 | 2002 | 1 | |
| 19 | Biological therapies for breast carcinoma: concepts for improvement in survival. | 1999 | 16 |
| 20 | 1995 | 78 |
About L. Esserman
L. Esserman is a scholar working on Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Immunology, having authored 39 papers that have together received 703 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (11 papers), Cancer Genomics and Diagnostics (6 papers), BRCA gene mutations in cancer (3 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers), Breast Implant and Reconstruction (3 papers), Advanced Breast Cancer Therapies (3 papers), Cancer Treatment and Pharmacology (3 papers) and MRI in cancer diagnosis (2 papers). The work is most often cited by research in Statistics and Probability (207 citations), Cancer Research (261 citations), Oncology (168 citations), Economics and Econometrics (106 citations) and Management Science and Operations Research (46 citations). L. Esserman has collaborated with scholars based in United States, Switzerland and Belgium. Frequent co-authors include NM Hylton, Kelloff Gj, DA Berry, Amy M. Fulton, Mark Shoemaker, Ernest C. Borden, Michael J. Campbell, Marion Campbell, Corina Marx and Zoran Antonijevic. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Clinical Pharmacology & Therapeutics and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.